Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium
Open Access
- 30 May 2020
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (5), 1067-1077
- https://doi.org/10.1002/cpt.1911
Abstract
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss‐of‐function alleles play an important role in this response, but account for only a small proportion of variability in response to clopidogrel. An aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify other genetic determinants of clopidogrel pharmacodynamics and clinical response. A genomewide association study (GWAS) was performed using DNA from 2,750 European ancestry individuals, using adenosine diphosphate‐induced platelet reactivity and major cardiovascular and cerebrovascular events as outcome parameters. GWAS for platelet reactivity revealed a strong signal for CYP2C19*2 (P value = 1.67e−33). After correction for CYP2C19*2 no other single‐nucleotide polymorphism reached genomewide significance. GWAS for a combined clinical end point of cardiovascular death, myocardial infarction, or stroke (5.0% event rate), or a combined end point of cardiovascular death or myocardial infarction (4.7% event rate) showed no significant results, although in coronary artery disease, percutaneous coronary intervention, and acute coronary syndrome subgroups, mutations in SCOS5P1, CDC42BPA, and CTRAC1 showed genomewide significance (lowest P values: 1.07e−09, 4.53e−08, and 2.60e−10, respectively). CYP2C19*2 is the strongest genetic determinant of on‐clopidogrel platelet reactivity. We identified three novel associations in clinical outcome subgroups, suggestive for each of these outcomes.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (U01HL105198, R24GM61374)
- National Institute of General Medical Sciences
- Robert Bosch Stiftung
- National Heart, Lung, and Blood Institute (R01 HL137922)
This publication has 47 references indexed in Scilit:
- Pharmacogenetics in Cardiovascular MedicinePublished by Elsevier BV ,2018
- Pharmacogenomics in the clinicNature, 2015
- CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysisJournal of Huazhong University of Science and Technology [Medical Sciences], 2015
- Clinical implications of drug–drug interactions with P2Y12 receptor inhibitorsJournal of Thrombosis and Haemostasis, 2014
- Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and BleedingJournal of the American College of Cardiology, 2013
- Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention: A Collaborative Meta-Analysis of Individual Participant DataJournal of the American College of Cardiology, 2011
- Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent PlacementJournal of the American College of Cardiology, 2010
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2009
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantationPharmacogenomics, 2008